...
search icon
ncna-img

NuCana PLC, Common Stock

NCNA

NAQ

$1.06

+$0.1

(10.42%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.16M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
73.96K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.96
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.85 L
$11 H
$1.06

About NuCana PLC, Common Stock

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNCNASectorS&P500
1-Week Return19.98%0.54%0.54%
1-Month Return-7.83%3.28%1.66%
3-Month Return-17.19%3.01%3.83%
6-Month Return-87.54%-4.69%9.77%
1-Year Return-87.31%1.41%23.47%
3-Year Return-98.53%15.72%42.73%
5-Year Return-99.12%42.38%82.01%
10-Year Return-99.74%103.91%190.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses25.68M32.95M45.36M43.72M31.13M[{"date":"2019-12-31","value":56.61,"profit":true},{"date":"2020-12-31","value":72.63,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.37,"profit":true},{"date":"2023-12-31","value":68.61,"profit":true}]
Operating Income(26.70M)(36.42M)(47.91M)(39.12M)(32.78M)[{"date":"2019-12-31","value":-2670000000,"profit":false},{"date":"2020-12-31","value":-3642100000,"profit":false},{"date":"2021-12-31","value":-4790500000,"profit":false},{"date":"2022-12-31","value":-3912200000,"profit":false},{"date":"2023-12-31","value":-3278400000,"profit":false}]
Total Non-Operating Income/Expense2.10M(3.01M)(2.35M)5.91M1.51M[{"date":"2019-12-31","value":35.49,"profit":true},{"date":"2020-12-31","value":-50.85,"profit":false},{"date":"2021-12-31","value":-39.82,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":25.51,"profit":true}]
Pre-Tax Income(25.65M)(36.17M)(47.80M)(38.45M)(32.03M)[{"date":"2019-12-31","value":-2565100000,"profit":false},{"date":"2020-12-31","value":-3617500000,"profit":false},{"date":"2021-12-31","value":-4780200000,"profit":false},{"date":"2022-12-31","value":-3845300000,"profit":false},{"date":"2023-12-31","value":-3203000000,"profit":false}]
Income Taxes(4.24M)(5.49M)(7.27M)(6.43M)(4.40M)[{"date":"2019-12-31","value":-423900000,"profit":false},{"date":"2020-12-31","value":-549300000,"profit":false},{"date":"2021-12-31","value":-726900000,"profit":false},{"date":"2022-12-31","value":-643200000,"profit":false},{"date":"2023-12-31","value":-439800000,"profit":false}]
Income After Taxes(21.41M)(30.68M)(40.53M)(32.02M)(27.63M)[{"date":"2019-12-31","value":-2141200000,"profit":false},{"date":"2020-12-31","value":-3068200000,"profit":false},{"date":"2021-12-31","value":-4053300000,"profit":false},{"date":"2022-12-31","value":-3202100000,"profit":false},{"date":"2023-12-31","value":-2763200000,"profit":false}]
Income From Continuous Operations(21.41M)(30.68M)(40.53M)(32.02M)(27.63M)[{"date":"2019-12-31","value":-2141200000,"profit":false},{"date":"2020-12-31","value":-3068200000,"profit":false},{"date":"2021-12-31","value":-4053300000,"profit":false},{"date":"2022-12-31","value":-3202100000,"profit":false},{"date":"2023-12-31","value":-2763200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(21.41M)(30.68M)(40.53M)(32.02M)(27.63M)[{"date":"2019-12-31","value":-2141200000,"profit":false},{"date":"2020-12-31","value":-3068200000,"profit":false},{"date":"2021-12-31","value":-4053300000,"profit":false},{"date":"2022-12-31","value":-3202100000,"profit":false},{"date":"2023-12-31","value":-2763200000,"profit":false}]
EPS (Diluted)(67.00)(79.00)(72.00)(32.00)(388.00)[{"date":"2019-12-31","value":-6700,"profit":false},{"date":"2020-12-31","value":-7900,"profit":false},{"date":"2021-12-31","value":-7200,"profit":false},{"date":"2022-12-31","value":-3200.12,"profit":false},{"date":"2023-12-31","value":-38800,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NCNA
Cash Ratio 0.76
Current Ratio 1.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NCNA
ROA (LTM) -69.75%
ROE (LTM) -199.06%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NCNA
Debt Ratio Lower is generally better. Negative is bad. 0.78
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.22

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NCNA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.67
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.30

FAQs

What is NuCana PLC share price today?

NuCana PLC (NCNA) share price today is $1.06

Can Indians buy NuCana PLC shares?

Yes, Indians can buy shares of NuCana PLC (NCNA) on Vested. To buy NuCana PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NCNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of NuCana PLC be purchased?

Yes, you can purchase fractional shares of NuCana PLC (NCNA) via the Vested app. You can start investing in NuCana PLC (NCNA) with a minimum investment of $1.

How to invest in NuCana PLC shares from India?

You can invest in shares of NuCana PLC (NCNA) via Vested in three simple steps:

  • Click on Sign Up or Invest in NCNA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in NuCana PLC shares
What is NuCana PLC 52-week high and low stock price?

The 52-week high price of NuCana PLC (NCNA) is $11. The 52-week low price of NuCana PLC (NCNA) is $0.85.

What is NuCana PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of NuCana PLC (NCNA) is 0.67

What is the Market Cap of NuCana PLC?

The market capitalization of NuCana PLC (NCNA) is $4.16M

What is NuCana PLC’s stock symbol?

The stock symbol (or ticker) of NuCana PLC is NCNA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top